Shanghai Kehua Bio-Engineering Co Ltd - Asset Resilience Ratio

Latest as of March 2026: 0.01%

Shanghai Kehua Bio-Engineering Co Ltd (002022) has an Asset Resilience Ratio of 0.01% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Shanghai Kehua Bio-Engineering Co Ltd current assets vs equity to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

CN¥305.66K
≈ $44.73K USD Cash + Short-term Investments

Total Assets

CN¥4.55 Billion
≈ $665.33 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2002–2025)

This chart shows how Shanghai Kehua Bio-Engineering Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Shanghai Kehua Bio-Engineering Co Ltd assets under control.

Liquid Assets Composition Over Time

This chart breaks down Shanghai Kehua Bio-Engineering Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Shanghai Kehua Bio-Engineering Co Ltd strategic investment ratio to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥305.66K 0.01%
Total Liquid Assets CN¥305.66K 0.01%

Asset Resilience Insights

  • Limited Liquidity: Shanghai Kehua Bio-Engineering Co Ltd maintains only 0.01% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Shanghai Kehua Bio-Engineering Co Ltd Industry Peers by Asset Resilience Ratio

Compare Shanghai Kehua Bio-Engineering Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Cochlear Ltd
AU:COH
Medical Devices 9.76%
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
Medical Devices 0.84%
Jafron Biomedical Co Ltd
SHE:300529
Medical Devices 34.37%
Stratec SE
XETRA:SBS
Medical Devices 0.29%
Shinhung
KO:004080
Medical Devices 4.17%
DRTECH Corporation
KQ:214680
Medical Devices 5.18%
Novacyt
PA:ALNOV
Medical Devices 0.02%
Diagnostic Medical Systems SA
PA:ALDMS
Medical Devices 1.48%

Annual Asset Resilience Ratio for Shanghai Kehua Bio-Engineering Co Ltd (2002–2025)

The table below shows the annual Asset Resilience Ratio data for Shanghai Kehua Bio-Engineering Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 1.30% CN¥60.36 Million
≈ $8.83 Million
CN¥4.64 Billion
≈ $679.19 Million
+1.29pp
2024-12-31 0.01% CN¥293.59K
≈ $42.96K
CN¥5.24 Billion
≈ $766.21 Million
-4.65pp
2023-12-31 4.65% CN¥316.77 Million
≈ $46.35 Million
CN¥6.81 Billion
≈ $996.19 Million
+4.63pp
2018-12-31 0.03% CN¥962.53K
≈ $140.85K
CN¥3.50 Billion
≈ $512.71 Million
+0.01pp
2010-12-31 0.02% CN¥234.08K
≈ $34.25K
CN¥1.09 Billion
≈ $159.05 Million
-0.02pp
2009-12-31 0.04% CN¥363.28K
≈ $53.16K
CN¥925.84 Million
≈ $135.48 Million
-0.28pp
2006-12-31 0.32% CN¥1.56 Million
≈ $228.10K
CN¥484.49 Million
≈ $70.90 Million
-4.11pp
2002-12-31 4.43% CN¥10.00 Million
≈ $1.46 Million
CN¥225.50 Million
≈ $33.00 Million
--
pp = percentage points

About Shanghai Kehua Bio-Engineering Co Ltd

SHE:002022 China Medical Devices
Market Cap
$422.24 Million
CN¥2.89 Billion CNY
Market Cap Rank
#13233 Global
#3941 in China
Share Price
CN¥5.61
Change (1 day)
-0.18%
52-Week Range
CN¥4.58 - CN¥7.09
All Time High
CN¥29.42
About

Shanghai Kehua Bio-Engineering Co.,Ltd, together with its subsidiaries, engages in the research, development, production, and sale of in vitro diagnostic reagents and medical testing equipment and services in China and internationally. The company offers immunoassay and clinical chemistry systems, HIV colloid gold test kits, ELISA HBV test kits, renal disease management solution, and automated co… Read more